Disclosed herein are compounds of formula I or salts thereof. In some embodiments, provided compounds are useful as Nav1.8 antagonists. In some embodiments, provides methods for preventing or treating Nav1.8-associated conditions, disorders or diseases.
C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
C07D 411/02 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
2.
USE OF COMPOUND IN PREPARATION OF DRUG FOR TREATING PSORIASIS
Use of a compound in the preparation of a drug for treating psoriasis. Particularly, disclosed is new use of lefamulin or retapamulin in the preparation of a drug for treating psoriasis. The experiment proves that lefamulin or retapamulin has significant efficacy in treating psoriasis with rapid onset of action and small toxic and side effects, is a safe, efficient, and stable drug for treating psoriasis with a simple preparation process, is suitable for industrial production, and is easy to popularize, thereby providing a new drug source for treating psoriasis.
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/215 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
Among other things, the present disclosure provides compounds of formula I or salts thereof. In some embodiments, provided compounds are useful as TRPV3 inhibitors. In some embodiments, the present disclosure provides methods for preventing or treating TRPV3-associated conditions, disorders or diseases.
patents